PSMA ADC

DRUG5 trials

Sponsors

Progenics Pharmaceuticals, Inc., Heinrich Elinzano, MD

Conditions

GBMGlioblastoma MultiformeGliosarcomaProstate Cancer

Phase 1

Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer

CompletedNCT01414283

Progenics Pharmaceuticals, Inc.Prostate Cancer

Start: 2008-10-31End: 2013-09-30Updated: 2013-11-01

Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer

CompletedNCT01414296

Progenics Pharmaceuticals, Inc.Prostate Cancer

Start: 2009-01-31End: 2013-11-30Updated: 2013-11-14

Phase 2

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

CompletedNCT01695044

Progenics Pharmaceuticals, Inc.Prostate Cancer

Start: 2012-09-30End: 2015-02-28Updated: 2017-03-24

BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)

CompletedNCT01856933

Heinrich Elinzano, MDGBM, Glioblastoma Multiforme, Gliosarcoma

Start: 2013-05-31End: 2015-02-28Updated: 2021-11-23

An Open-label Extension Study of PSMA ADC 2301 in mCRPC

CompletedNCT02020135

Progenics Pharmaceuticals, Inc.Prostate Cancer

Start: 2013-10-31End: 2015-03-31Updated: 2017-03-24

Related Papers

PSMA ADC for progressive glioblastoma: Phase II Brown University Oncology Research Group Study.

Journal of Clinical Oncology2016-05-2010 citations

A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following abiraterone and/or enzalutamide (abi/enz).

Journal of Clinical Oncology2015-03-0125 citations

A phase 2 trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2014-05-2012 citations

A phase II trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2014-02-0120 citations